Skip to main content

Investor Relations

Our Story

Chembio is Well-Positioned in the Point-of-Care Diagnostic Testing Market

Patented Innovative Dual Path Platform (DPP®) Technology Enables Multiplex Capability With Broad Diagnostic Applications

Broad Product Pipeline in Infectious Disease

Strong Management Team With 200+ Years of Cumulative Experience

Building DPP SARS-CoV-2 Portfolio of Highly Differentiated Tests for Both Antigen and Antibody

Offering High Value Diagnostic Products Targeted At Large Markets

Corporate Profile

Subscribe to the Chembio Mailing List